180 related articles for article (PubMed ID: 36355260)
1. Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Chidley P; Shanker M; Phillips C; Haghighi N; Pinkham MB; Whittle JR; Sia J
J Neurooncol; 2022 Nov; 160(2):361-374. PubMed ID: 36355260
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
5. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Pedretti S; Masini L; Turco E; Triggiani L; Krengli M; Meduri B; Pirtoli L; Borghetti P; Pegurri L; Riva N; Gatta R; Fusco V; Scoccianti S; Bruni A; Ricardi U; Santoni R; Magrini SM; Buglione M
J Neurooncol; 2019 Jul; 143(3):447-455. PubMed ID: 31054101
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Guo L; Li X; Chen Y; Liu R; Ren C; Du S
Cancer Radiother; 2021 Apr; 25(2):182-190. PubMed ID: 33436285
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
11. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
13. Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Saeed H; Tseng YD; Lo SS
Ann Palliat Med; 2021 Jan; 10(1):846-862. PubMed ID: 33040565
[TBL] [Abstract][Full Text] [Related]
14. Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
Mallick S; Gupta S; Amariyil A; Kunhiparambath H; Laviraj MA; Sharma S; Sagiraju HKR; Julka PK; Sharma D; Rath GK
J Neurooncol; 2023 Aug; 164(1):141-146. PubMed ID: 37452916
[TBL] [Abstract][Full Text] [Related]
15. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
16. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
[TBL] [Abstract][Full Text] [Related]
17. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M
J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
Lu VM; Kerezoudis P; Brown DA; Burns TC; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Jun; 143(2):177-185. PubMed ID: 30919157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
